Biotech | October 31, 2023
Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
Subscribe To Our Newsletter & Stay Updated
